1-2 of 2
Peter Kelemen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Philipp Bernhard Staber, MD PhD, Wojciech Jurczak, Wolfram Brugger, Asher A. Chanan-Khan, MD, Richard Greil, MD, Andrzej Hellmann, MD PhD, Maren Dirnberger-Hertweck, PhD, Peter Kelemen, Jan Moritz Middeke, MD, Marco Montillo, MD, Marina Motta, MD, Talha Munir, MD, Peter Neumeister, MD, Dietger Niederweiser, MD, Sameer A. Parikh, MD, Johannes Schetelig, MDMSc, Stephan Stilgenbauer, Vladan Vucinic, MD, Johannes Weirather, PhD, Jennifer Woyach, MD, Clemens-Martin Wendtner
Journal: Blood
Blood (2019) 134 (Supplement_1): 1754.
https://doi.org/10.1182/blood-2019-128388
Published: 2019
Journal Articles

Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy

Philipp Bernhard Staber, MD PhD, Asher A. Chanan-Khan, MD, Talha Munir, Dietger Niederweiser, Johannes Schetelig, MD MSc, Jan Moritz Middeke, MD, Maren Dirnberger-Hertweck, PhD, Peter Kelemen, Johannes Weirather, PhD, Sameer A. Parikh, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Jennifer A. Woyach, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4433.
https://doi.org/10.1182/blood-2018-99-114489
Published: 2018